Alitair Pharmaceuticals Overview

  • Founded
  • 2010
Founded
  • Status
  • Private
  • Employees
  • 3
Employees
  • Latest Deal Type
  • Angel
  • Latest Deal Amount
  • $35K
Latest Deal Amount

Alitair Pharmaceuticals General Information

Description

Operator of a specialty pharmaceutical company intended to develop proprietary ion-exchange resin formulations, prescription cough medicines and a pipeline of orphan drugs. The company's patented formulation acts as a passive drug formulation system to reduce the risk of prescription drug overdose irrespective of the number of tablets or capsules ingested, enabling medical professionals to treat bronchiectasis easily and patients to get relief from respiration-related diseases quickly.

Contact Information

Website
www.alitairpharmaceuticals.com
Formerly Known As
The Cough Company
Ownership Status
Privately Held (backing)
Financing Status
Angel-Backed
Primary Industry
Pharmaceuticals
Other Industries
Drug Discovery
Primary Office
  • 55 Madison Avenue
  • Suite 400
  • Morristown, NJ 07960
  • United States
+1 (877) 000-0000

Alitair Pharmaceuticals Timeline

2018201920202021
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Alitair Pharmaceuticals Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Angel (individual) 11-Nov-2020 $35K 00.000 Completed Clinical Trials - General
4. Angel (individual) 09-Oct-2018 00000 00.000 Completed Clinical Trials - General
3. Angel (individual) 29-Jun-2017 000 00.00 Completed Clinical Trials - General
2. Angel (individual) 10-Feb-2017 $100K $100K Completed Clinical Trials - General
1. Angel (individual) 29-Sep-2015 $911K Completed Clinical Trials - General
To view Alitair Pharmaceuticals’s complete valuation and funding history, request access »

Alitair Pharmaceuticals Executive Team (6)

Name Title Board Seat Contact Info
James Hoyes Chief Executive Officer & Chairman
Helmut Albrecht MD Chief Scientific Officer
Frank Guarino Senior Vice President, Finance
Frank Koos Senior Vice President, Business Development
You’re viewing 4 of 6 executive team members. Get the full list »

Alitair Pharmaceuticals Board Members (3)

Name Representing Role Since
James Hoyes Alitair Pharmaceuticals Chief Executive Officer & Chairman 000 0000
Robert Casale Alitair Pharmaceuticals Board Member 000 0000
You’re viewing 2 of 3 board members. Get the full list »

Alitair Pharmaceuticals Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Ready to get started?

Request a free trial